Rising incidence of prostate cancer in Scotland: Increased risk or increased detection?

BJU International

Volumn 85, Issue 4, 2000, Pages 463-473

  Brewster, D H ^a   Fraser, L A ^a   Harris, V ^a   Black, R J ^a  

^a HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

Author keywords

Epidemiology; Incidence; Mortality; Prostate specific antigen; Prostatic neoplasms; Transurethral resection of the prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; EARLY DIAGNOSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; TRANSURETHRAL RESECTION; UNITED KINGDOM;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESIDENCE CHARACTERISTICS; RISK FACTORS; SCOTLAND; SURVIVAL RATE; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 0034051060     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00487.x     Document Type: Article

References (53)

1. 1 Coleman MP, Estève J, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mortality. IARC Scientific Publications No. 121. Lyon: International Agency for Research on Cancer, 1993
2. 2 Whittemore AS. Prostate Cancer. In Doll R, Fraumeni JF Jr, Muir CS, eds. Trends in Cancer Incidence and Mortality. Cancer Surveys. 19/20. New York: Cold Spring Harbor Laboratory Press, 1994:309-22
3. 3 Swerdlow AJ, dos Santos Silva I, Reid A, Qiao Z, Brewster DH, Arrundale J. Trends in cancer incidence and mortality in Scotland: description and possible explanations. Br J Cancer 1998; 77 (Suppl 3): 1-16
4. 4 Harris V, Sandridge AL, Black RJ, Brewster DH, Gould A. Cancer Registration Statistics Scotland 1986-95. Edinburgh: ISD Scotland, 1998
5. 5 Information and Statistics Division. Scottish Health Statistics 1998. Edinburgh: ISS Scotland, 1999
6. 6 Alexander FE, Boyle P. The rise in prostate cancer: myth or reality? In Garraway M, ed. Epidemiology of Prostate Disease. Berlin, Heidelberg: Springer Verlag, 1995
7. 7 Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer Incidence in Five Continents. Vol VII IARC Scientific Publications No 143 Lyon: International Agency for Research on Cancer, 1997
8. 8 UK National Screening Committee. First Report of the National Screening Committee. London: Department of Health, 1998
9. 9 Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997; 1
10. 10 Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997; 1
11. 11 NHS Centre for Reviews and Dissemination. Screening for prostate cancer. Effectiveness Matters 1997; 2
12. 12 Boyle P. Prostate specific antigen (PSA) testing as screening for prostate cancer: The current controversy. Ann Oncol 1998; 9: 1263-4
13. 13 World Health Organisation. International Classification of Diseases, 1975. Ninth revision. Geneva: WHO, 1977
14. 14 Scottish Cancer Intelligence Unit. Annual Report 1996/97. Edinburgh: Information & Statistics Division, 1997
15. 15 Registrar General for Scotland. Annual Reports 1981-96. Edinburgh: HMSO, 1982-97
16. 16 ISD Scotland. ISD Guide. Edinburgh: Information & Statistics Division, 1996
17. 17 Office of Population Censuses and Surveys. Classification of Surgical Operations. Third Revision. London: OPCS, 1975
18. 18 Office of Population Censuses and Surveys. Tabular List of the Classification of Surgical Operations and Procedures. Fourth Revision. London: OPCS, 1990
19. 19 Waterhouse J, Muir C, Correa P, Powell J, eds. Cancer Incidence in Five Continents. Vol III IARC Scientific Publications No 15 Lyon: International Agency for Research on Cancer, 1976
20. 20 Estève J, Benhamou E, Raymond L. Statistical Methods in Cancer Research. IV. Descriptive Epidemiology. IARC Scientific Publications, 128. Lyon: International Agency for Research on Cancer, 1994
21. 21 Bain M, Chalmers JWT, Brewster DH. Routinely collected data in national and regional databases - an under used resource. J Public Health Med 1997; 19: 413-8
22. 22 Brewster D, Crichton J, Muir C. How accurate are Scottish cancer registration data? Br J Cancer 1994; 70: 954-9
23. 23 Brewster D, Crichton J, Harvey JC, Dawson G, Nairn ER. Benefits and limitations of pathology databases to cancer registries. J Clin Pathol 1996; 49: 947-9
24. 24 Brewster D, Crichton J, Harvey JC, Dawson G. Completeness of case ascertainment in a Scottish Regional Cancer Registry for the year 1992. Public Health 1997; 111: 339-43
25. 25 Cameron HM, McGoogan E. A prospective study of 1152 hospital autopsies: I. Inaccuracies in death certification. J Pathol 1981; 133: 273-83
26. 26 Grulich AE, Swerdlow AJ, dos Santos Silva I, Beral V. Is the apparent rise in cancer mortality in the elderly real? Analysis of changes in certification and coding of cause of death in England and Wales, 1970-90. Int J Cancer 1995; 63: 164-8
27. 27 Harley K, Jones C. Quality of Scottish Morbidity Record (SMR) data. Health Bull 1996; 54: 410-7
28. 28 Stanford JL, Stephenson RA, Coyle LM et al. Prostate Cancer Trends 1973-95. SEER Program, National Cancer Institute. Bethesda: National Institutes of Health, 1999; in press. (Available at http://www-seer.ims.nci.nih.gov/ Publications/ProstMono/)
29. 29 Threlfall TJ, English DR, Rouse IL. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust 1998; 169: 21-4
30. 30 Levy IG, Gibbons L, Collins JP, Perkins DG, Mao Y. Prostate cancer trends in Canada: Rising incidence or increased detection? Can Med Assoc J 1993; 149: 617-24
31. 31 Post PN, Straatman H, Kiemeney LALM, Coebergh J-WW. Increased risk of fatal prostate cancer may explain the rise in mortality in the Netherlands. Int J Epidemiol 1999; 28: 403-8
32. 32 Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer associated with increased use of transurethral resection. J Natl Cancer Inst 1990; 82: 1624-8
33. 33 Corder EH, Chute CG, Guess HA, Beard CM, O'Fallon WM, Lieber MM. Prostate cancer in Rochester, Minnesota (USA), from 1935 to 1989: increases in incidence related to more complete ascertainment. Cancer Causes Control 1994; 5: 207-14
34. 34 Office for National Statistics. Cancer statistics - registrations. Series MB1 no. 25. London. HMSO, 1998
35. 35 Office for National Statistics. Estimates of newly diagnosed cases of cancer, England and Wales, 1993-97. Monitor MB1 98/2. London: ONS, 1998
36. 36 Smith DP, Armstrong BK. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust 1998; 169: 17-20
37. 37 Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-52
38. 38 Tretli S, Engeland A, Haldorsen T et al. Prostate cancer -look to Denmark? J Natl Cancer Inst 1996; 88: 128
39. 39 Brawley OW. Prostate cancer incidence and patient mortality: the effects of screening and early detection. Cancer 1997; 80: 1857-63
40. 40 Goodman CM on behalf of the Scottish Urological Oncology Group and Scottish Cancer Therapy Network. Audit of prostate cancer management in Scotland: 1988 and 1993. Br J Urol 1997; 79 (Suppl 4): 7
41. 41 Post PN, Stockton D, Davies TW, Coebergh J-WW. Striking increase in incidence of prostate cancer in men aged < 60 years without improvement in prognosis. Br J Cancer 1999; 79: 13-7
42. 42 Hicks RJ, Hamm RM, Bemben DA. Prostate cancer screening. What family physicians believe is best. Arch Fam Med 1995; 4: 317-22
43. 43 Ward JE, Gupta L, Taylor NJ. Do general practitioners use prostate-specific antigen as a screening test for early prostate cancer? Med J Aust 1998; 169: 29-31
44. 44 McGing PG. A study of PSA requests from general practitioners received by one Dublin hospital. Irish Med J 1998; 91: 61-2
45. 45 Gann PH. Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology 1997; 8: 117-20
46. 46 Meyer F, Moore L, Bairati I, Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999; 161: 1189-91
47. 47 Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death: the first analysis of the 1988 Quebec prospective randomised controlled trial. Prostate 1999; 38: 83-91
48. 48 Alexander FE, Prescott RJ. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomised controlled trial [letter]. Prostate 1999; 40: 135-7
49. 49 Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994; 152: 1905-9
50. 50 Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer 1997; 80: 1830-4
51. 51 Frydenberg M, Stricker PD, Kaye KW. Prostate cancer diagnosis and management. Lancet 1997; 349: 1681-7
52. 52 McCredie M, Cox B. Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust 1998; 169: 9-10
53. 53 Dearnaley DP, Kirby RS, Kirk D, Malone P, Simpson RJ, Williams G. Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party. BJU Int 1999; 83: 18-33